Fig. 3.

A. Box plots of differences in 28 immune cells in the training set, TCGA, and GEO validation sets, showing a significant increase in Macrophage in high-risk patients. B. High-risk patients exhibited an increase in IC50 for Methotrexate and Lenalidomide, but a decrease in IC50 for Cisplatin and Etoposide. C. High-risk patients showed a significant decrease in the responsiveness to immunotherapy, represented by TIDE, and a significant increase in the activation level of the interferon-γ (IFN-γ) signaling pathway, represented by IFNG.